Cite
HARVARD Citation
Lakhani, N. et al. (n.d.). 196TiP A phase I study of REGN6569, a GITR monoclonal antibody (mAb), in combination with cemiplimab in patients with advanced solid tumour malignancies. Immuno-oncology technology. p. . [Online].